Compare MYGN & MLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MYGN | MLAB |
|---|---|---|
| Founded | 1991 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 444.2M | 533.0M |
| IPO Year | 1996 | 1995 |
| Metric | MYGN | MLAB |
|---|---|---|
| Price | $6.29 | $95.10 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 7 | 1 |
| Target Price | $7.64 | ★ $94.00 |
| AVG Volume (30 Days) | ★ 1.5M | 182.2K |
| Earning Date | 05-05-2026 | 05-27-2026 |
| Dividend Yield | N/A | ★ 0.67% |
| EPS Growth | N/A | ★ 436.11 |
| EPS | N/A | ★ 1.21 |
| Revenue | ★ $771,400,000.00 | N/A |
| Revenue This Year | $6.86 | $6.07 |
| Revenue Next Year | $5.45 | $5.41 |
| P/E Ratio | ★ N/A | $77.99 |
| Revenue Growth | ★ 2.33 | N/A |
| 52 Week Low | $3.53 | $59.63 |
| 52 Week High | $8.59 | $113.99 |
| Indicator | MYGN | MLAB |
|---|---|---|
| Relative Strength Index (RSI) | 70.35 | 44.57 |
| Support Level | $6.09 | $94.01 |
| Resistance Level | $7.29 | $97.56 |
| Average True Range (ATR) | 0.34 | 4.91 |
| MACD | 0.02 | -0.42 |
| Stochastic Oscillator | 93.91 | 28.85 |
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.
Mesa Laboratories Inc manufactures life sciences tools and critical quality control products. It operates in four divisions: Sterilization and Disinfection Control, which manufactures and sells biological, chemical, and cleaning indicators used to assess the effectiveness of sterilization, decontamination, disinfection, and cleaning processes. Clinical Genomics division develops, manufactures, and sells highly sensitive, low-cost, high-throughput genetic analysis tools and related consumables. The Biopharmaceutical Development division develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. The Calibration Solutions division develops, manufactures, sells, and services quality control products.